Assembly Biosciences Announces Positive Phase 1b Results
I'm PortAI, I can summarize articles.
Assembly Biosciences (ASMB) announced positive interim results from its Phase 1b clinical study of ABI-5366, showing a 94% reduction in HSV-2 shedding and a 98% reduction in high viral load shedding compared to placebo. The results support potential once-weekly and once-monthly dosing regimens and pave the way for Phase 2 studies expected to start in mid-2026. Analysts rate ASMB stock as a Buy with a $31.00 price target, though concerns about financial challenges and negative cash flows remain.
Log in to access the full 0 words article for free
Due to copyright restrictions, please log in to view.
Thank you for supporting legitimate content.
Source: Tip Ranks The copyright of this article belongs to the original author/organization.
The views expressed herein are solely those of the author and do not reflect the stance of the platform. The content is intended for investment reference purposes only and shall not be considered as investment advice. Please contact us if you have any questions or suggestions regarding the content services provided by the platform.
Post your comment
No Comments